Efficacy,safety, tolerability,and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Efficacy,safety, tolerability,and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes

Authors:	Thomas R. Pieber MD Ronnie Aronson MD Mark P. Christiansen MD Bruce Bode MD Khaled Junaidi MD Valentina Conoscenti MD

Affiliation:	1. Medical University of Graz, Graz, Austria;2. LMC-Diabetes & Endocrinology, Toronto, Ontario, Canada;3. Diablo Clinical Research, Walnut Creek, California, USA;4. Atlanta Diabetes Associates, Atlanta, Georgia, USA;5. Xeris Pharmaceuticals, Inc., Chicago, Illinois, USA

Abstract:

Keywords:	glucagon severe hypoglycaemia type 1 diabetes